Cannabis use disorder among veterans: Comorbidity and mental health treatment utilization.

Cannabis use disorder (CUD) is the most common illicit substance use disorder in the United States and is related to a range of functional impairment. CUD is associated with comorbid mental health disorders and other substance use disorders, compounding impairment from either type of disorder alone. U.S. military veterans also experience CUD at high rates; however, less is known about comorbidity and its impact on service utilization among veterans. Better understanding of comorbidity in this group is important, given that the Veterans Health Administration is the largest U.S. healthcare provider and is uniquely positioned to potentially address the challenges of comorbid CUD. The current study aimed to examine rates of comorbidity among veterans with CUD and the impact of comorbidity on mental health service utilization. Data were obtained through national Veterans Health Administration administrative and clinical records from 2010 to 2016. 79.1% of veterans with CUD were also diagnosed with a mental health disorder, and 76.8% were diagnosed with another substance use disorder. Overall, veterans with CUD and a comorbid mental health disorder used more individual psychotherapy than those with CUD alone. These findings suggest that CUD among veterans is rarely diagnosed independent of other disorders and that comorbidity is associated with greater mental healthcare utilization. Improved screening for CUD and integration of its treatment within current models of care may be important to consider in large healthcare systems.

Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review.

BACKGROUND & AIMS: We conducted a systematic review of efficacy of psychosocial interventions in inducing or maintaining alcohol abstinence in patients with chronic liver disease (CLD) and alcohol use disorder (AUD). METHODS: We performed structured keyword searches in PubMed, PsychINFO, and MEDLINE for original research articles that were published from January 1983 through November 2014 that evaluated the use of psychosocial interventions to induce or maintain alcohol abstinence in patients with CLD and AUD. RESULTS: We identified 13 eligible studies that comprised 1945 patients; 5 were randomized controlled trials (RCTs). Delivered therapies included motivational enhancement therapy, cognitive behavioral therapy (CBT), motivational interviewing, supportive therapy, and psychoeducation either alone or in combination in the intervention group and general health education or treatment as usual in the control group. All studies of induction of abstinence (4 RCTs and 6 observational studies) reported an increase in abstinence among participants in the intervention and control groups. Only an integrated therapy that combined CBT and motivational enhancement therapy with comprehensive medical care, delivered during a period of 2 years, produced a significant increase in abstinence (74% increase in intervention group vs 48% increase in control group, P = .02), which was reported in 1 RCT. All studies of maintenance of abstinence (1 RCT and 2 observational studies) observed recidivism in the intervention and control groups. Only an integrated therapy that combined medical care with CBT produced a significantly smaller rate of recidivism (32.7% in integrated CBT group vs 75% in control group, P = .03), which was reported from 1 observational study. However, data were not collected for more than 2 years on outcomes of patients with CLD and AUD. CONCLUSIONS: In a systematic analysis of studies of interventions to induce or maintain alcohol abstinence in patients with CLD and AUD, integrated combination psychotherapy with CBT, motivational enhancement therapy, and comprehensive medical care increased alcohol abstinence. No psychosocial intervention was successful in maintaining abstinence, but an integrated therapy with CBT and medical care appears to reduce recidivism.

The influence of baseline marijuana use on treatment of cocaine dependence: application of an informative-priors bayesian approach.

BACKGROUND: Marijuana use is prevalent among patients with cocaine dependence and often non-exclusionary in clinical trials of potential cocaine medications. The dual-focus of this study was to (1) examine the moderating effect of baseline marijuana use on response to treatment with levodopa/carbidopa for cocaine dependence; and (2) apply an informative-priors, Bayesian approach for estimating the probability of a subgroup-by-treatment interaction effect. METHOD: A secondary data analysis of two previously published, double-blind, randomized controlled trials provided complete data for the historical (Study 1: N = 64 placebo), and current (Study 2: N = 113) data sets. Negative binomial regression evaluated Treatment Effectiveness Scores (TES) as a function of medication condition (levodopa/carbidopa, placebo), baseline marijuana use (days in past 30), and their interaction. RESULTS: Bayesian analysis indicated that there was a 96% chance that baseline marijuana use predicts differential response to treatment with levodopa/carbidopa. Simple effects indicated that among participants receiving levodopa/carbidopa the probability that baseline marijuana confers harm in terms of reducing TES was 0.981; whereas the probability that marijuana confers harm within the placebo condition was 0.163. For every additional day of marijuana use reported at baseline, participants in the levodopa/carbidopa condition demonstrated a 5.4% decrease in TES; while participants in the placebo condition demonstrated a 4.9% increase in TES. CONCLUSION: The potential moderating effect of marijuana on cocaine treatment response should be considered in future trial designs. Applying Bayesian subgroup analysis proved informative in characterizing this patient-treatment interaction effect.